IT

Laura Iris Ferro

This inventor holds 0 USPTO granted patents, plus 1 CIPO patent.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Laura Iris Ferro. Retrieved from https://idiyas.com/inventor/laura-iris-ferro-efakv59d

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...

Title: Laura Iris Ferro: Innovator in Anti-Tumor Formulations

Introduction

Laura Iris Ferro is a notable inventor based in Italy, recognized for her contributions to the field of anti-tumor formulations. Her innovative work focuses on the use of defibrotide as an anti-tumor agent, either alone or in combination with other active ingredients that possess anti-tumor properties.

Latest Patents

Laura Iris Ferro holds a patent titled "Anti-Tumor Formulations Comprising Defibrotide Alone Or In Combination With Other Anti-Tumor Agents." This patent describes the application of defibrotide as an effective anti-tumor agent, showcasing her commitment to advancing cancer treatment options. Despite having 0 patents, her research is significant in the medical field.

Career Highlights

Laura is currently employed at Gentium S.p.a., a company dedicated to developing innovative therapies for patients with serious medical conditions. Her role at Gentium S.p.a. allows her to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Throughout her career, Laura has collaborated with esteemed colleagues, including Massimo Iacobelli and Paul Richardson. These partnerships enhance her research efforts and contribute to the advancement of anti-tumor therapies.

Conclusion

Laura Iris Ferro is a dedicated inventor whose work in anti-tumor formulations is paving the way for new treatment options. Her innovative approach and collaborations with other professionals in the field highlight her commitment to improving patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…